Company Overview - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for endocrine and metabolic disorders [3] - The company is based in Carmel, Indiana and utilizes its proprietary PEP™ platform to advance its pipeline of candidates [3] Pipeline Development - The lead product candidate, MBX 2109, is in Phase 2 development for chronic hypoparathyroidism (HP) [3] - MBX 1416 is in Phase 1 development for post-bariatric hypoglycemia (PBH) [3] - The obesity portfolio includes MBX 4291 and multiple discovery and pre-clinical candidates aimed at treating obesity [3] Upcoming Investor Conferences - Kent Hawryluk, President and CEO, will present at the Guggenheim SMID Cap Biotechnology Conference on February 5, 2025, from 2:00 - 2:25 p.m. EST in New York, NY [1] - He will also participate in the BIO CEO & Investor Conference on February 10, 2025, from 11:00 a.m. – 12:00 p.m. EST in New York, NY [2] - Additionally, he will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference virtually on February 11, 2025, from 8:40 - 9:10 a.m. EST [2]
MBX Biosciences to Participate in Upcoming February Investor Conferences